FIS

FIS has been a top global leader in the contract and generic manufacturing of small molecule API and intermediates since 1957.
With an industrial network of four production sites, 1900 employees (250 of which are in R&D), commercial activities in 60 countries, and a solid track record in Quality and HSE, we are honored to support our customers in providing the best medicine to patients worldwide.
Our history teaches us that shareholder stability, company values, customer relationships, and competence are the ingredients of our past and future success.
The business lines are:
-Contract Development, delivered by 250 R&D experts
-Contract Manufacturing, ranging from small scale to large commercial productions
-Generic APIs including several TAs: CNS, controlled substances, antibacterials, anti-inflammatory drugs, diuretics, steroidal products, hormone replacement, cardiovascular drugs, alimentary tract and metabolism active substances
-Veterinary APIs and Intermediates

Our commercial teams are committed to serve our customers in over 60 countries
FIS Japan has established in 2019 to support our customers in Japan.